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BACKGROUND: AZD1152, the prodrug for AZD1152-hydroxyquinazoline pyrazol anilide (HQPA), is a selective inhibitor of Aurora B
kinase activity. Preclinical evaluation of AZD1152 has been reported in several human cancer models. The potentiality of this
compound in combination therapy warrants further investigation in solid tumours.
EXPERIMENTAL DESIGN: This study explored the effects of AZD1152-HQPA in colon and pancreatic tumour cells. The antitumour
properties of AZD1152, either as single agent or in combination with chemotherapeutics, were evaluated in each study model. The
efficacy and the toxicity of AZD1152 alone and in combination with gemcitabine were validated in pancreatic tumour xenograft
model.
RESULTS: AZD1152-HQPA treatment resulted in a dramatic increase of chromosome number, modification of cell cycle and induction
of apoptosis. The most effective combination was that with chemotherapeutics given soon after AZD1152 in both tumour cell types.
The effectiveness of the sequential schedule of AZD1152 with gemcitabine was confirmed in nude mice bearing MiaPaCa-2 tumours,
showing inhibition of tumour volumes and delaying of tumour growth after the interruption of the treatments.
CONCLUSION: Here we show that AZD1152-HQPA enhances oxaliplatin and gemcitabine effectiveness in colon and pancreatic
cancer, respectively. First, we provide advances into administration schedules and dosing regimens for the combination treatment in
in vivo pancreatic tumour.
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The Aurora family comprises three related kinases, namely A, B
and C; expression of the first two is closely linked to the
proliferation of many cell types, although the role of the third one
is not yet clearly defined (Katayama et al, 2003). Increased cellular
levels of these kinases may be related to genetic instability and is
evident in various cancer types including breast, ovarian, colon
and pancreatic. Aurora A kinase is located in the pericentriolar
region where its function is related to centrosome function and
duplication, mitotic entry and bipolar spindle assembly (Lukasie-
wicz and Lingle, 2009). During its activity in metaphase, the kinase
migrates to mitotic spindle poles and mid-zone microtubules,
phosphorylating and recruiting several microtubule-associated
proteins to the centrosome to promote maturation. Aurora B,
together with survivin, INCENP and borealin, forms the chromo-
somal passenger complex and acts as its catalytic component
allowing (i) correct segregation of chromatids at mitosis, (ii)
histone H3 phosphorylation, an event probably related to
chromosome condensation and (iii) cytokinesis (Vogt et al,
2009). Aurora C kinase appears to have a role similar to that of
Aurora B kinase, but its expression appears to be restricted to the
testis (Sen, 2009).
All these characteristics make this family of kinases an attractive
target for tailored anticancer therapy.
Several small-molecule inhibitors of Aurora kinases have been
developed and are currently in early clinical evaluation, including
AZD1152 (Schellens et al, 2006; Boss et al, 2009). AZD1152 is a
dihydrogen phosphate prodrug of a pyrazoloquinazoline Aurora
kinase inhibitor (AZD1152-hydroxyquinazoline pyrazol anilide
(HQPA)) that is rapidly converted into the active moiety
AZD1152-HQPA following parental administration in vivo.
AZD1152-HQPA is a highly potent and selective inhibitor of
Aurora B (Ki 0.36nmoll
 1) compared with Aurora A (Ki
1.3669nmoll
 1) and has high selectivity vs a panel of 50 other
kinases (Keen et al, 2005).
In several preclinical models, AZD1152 has shown significant
inhibition of tumour growth both as a monotherapy and in
combination with ionising radiation and chemotherapeutic agents
including vincristine, daunorubicin and CPT-11 (Wilkinson et al,
2007; Yang et al, 2007; Evans et al, 2008; Tao et al, 2008; Walsby
et al, 2008; Ikezoe et al, 2009; Nair et al, 2009a,b; Oke et al, 2009).
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sIn 2006 ASCO Annual meeting and in 2010, Schellens and
co-workers presented preliminary results of a phase I clinical trial
performed with AZD1152 in patients with advanced solid tumours
(Schellens et al, 2006; Boss et al, 2010). They reported significant
disease stabilisation suggesting a future promising clinical
development for this agent, which showed maximum-tolerated
doses (MTDs) of 200 and 450mg, DLT of 450mg, significant non-
haematological toxicities and a clearance of 22.4±1.03lh
 1.
Another clinical trial, a phase I/II, open-label two-part study,
provided information on the safety and efficacy of AZD1152 in
patients with advanced acute myeloid leukaemia showing that this
agent had an acceptable tolerability profile in patients with acute
myeloid leukaemia (AML) (Lowenberg et al, 2009). The MTD of
AZD1152, given as a continuous 7-day infusion every 21 days,
was 1200mg and the overall clinical response rate was of 23%.
Currently, AZD1152 is being evaluated in phase II trials
as monotherapy or in combination with low-dose cytosine
arabinoside for the treatment of elderly patients with AML
who are unsuitable for standard induction treatment (www.
clinicaltrials.gov).
The main open questions in considering Aurora kinase
inhibitors as promising anticancer drugs are the possible
predictive factors for response and their combination with other
cytotoxic agents.
These topics are explored only limitedly, and among possible
predictive factors, it was suggested CHFR, a mitotic checkpoint
protein and p53, the inactivation of which leads to increased
sensitivity to this class of drugs (Nair et al, 2005; Summers et al,
2005; Yu et al, 2005). For what concerns data on Aurora kinase
inhibitors in combination with chemotherapeutic drugs, more
literature evidences are available, in particular with daunorubicin,
SN-38, vinorelbine, gemcitabine, docetaxel, oxaliplatin and
5-fluorouracil (Nair et al, 2004; Soncini et al, 2006; Hoover, 2007).
However, the exploration of mechanisms responsible for Aurora
kinase inhibition, its regulation, downstream effectors and
upstream regulators after AZD1152 administration provides a
rapid progress in understanding the complex mechanism of action
of this relatively new class of drugs that enlighten their utilisation
in clinical practice.
Our interest lies in the use of Aurora kinase inhibitors in
combination with chemotherapy in solid tumours and experiments
reported in this paper were carried out in colon and pancreatic
cancer cells.
The selection of in vitro models is justified by the high levels of
Aurora kinases, related to genetic instability (Kimura et al, 1999),
in a wide range of human cancers, including colorectal and
pancreatic cancers (Katayama et al, 1999; Warner et al, 2006).
Advances in chemotherapy have led to changes in treatment
practice standards and improved survival for colorectal cancer
patients. Platinum-based chemotherapeutics, camptothecins and
5-FU, remain the cornerstone chemotherapy drugs for colorectal
cancer; however, today they are administered as part of multidrug
regimens (Muggia and Fojo, 2004; Hegde et al, 2008; Cheung et al,
2009). New targeted therapies offer great promise against color-
ectal cancer. These therapies, including drugs and monoclonal
antibodies, target specific biological processes used by cancers to
grow and spread. Recent evidence has indicated that the induction
of apoptosis in human colon carcinoma cell system take advantage
from response to various antimitotic drug treatments, enforcing
the idea that targeting the mitotic kinases, such as Aurora B, is a
viable area of research for the exploitation of novel anticancer
strategies in the treatment of colorectal cancer patients.
In the literature, Nair and co-workers have already reported the
possibility to combine AD1152 with campothecins in in vitro and
in vivo colorectal cancer model (Nair et al, 2009a), and we decided
to confirm this hypothesis by investigating the effectiveness of this
drug in combination with the other conventional drug, the
oxaliplatin.
For what concerns pancreatic tumour, it is well known that it is
difficult to treat and is associated with a dismal prognosis. This
tumour spreads rapidly and, because it is difficult to detect in the
early stages of disease, most patients are not diagnosed until they
have metastatic disease. Consequently, the 5-year survival rate is
less than 2% (Wong and Lemoine, 2009) and there is a need for
novel therapeutic approaches based on the targets involved in
pancreatic carcinogenesis, including both signal-transduction and
embryonic development pathways. Recent pre-clinical studies on
novel therapeutic approaches have provided promising results
through multiple inhibition of the same pathway or through the
inhibition of multiple signalling pathways. These pharmacological
approaches should prevent the development of escape or
resistance mechanisms. The standard chemotherapeutic drug for
patients with advanced pancreatic cancer is gemcitabine, an
antimetabolite that is incorporated in the DNA to interfere with
the process of division of cancer cells, thus hindering their growth.
The limited encouraging data from clinical evaluation of
gemcitabine in association with chemotherapy or target-oriented
drugs, mainly inhibitors of tyrosine kinase receptor pathways,
suggest that a promising therapeutic approach could be enhanced
inhibition of mechanisms responsible for DNA synthesis, repair
and for correct cytokinesis by combining gemcitabine with Aurora
kinase inhibitors (Moufarij et al, 2003; Bayraktar et al, 2010).
Thus, we evaluated whether AZD1152 could enhance the efficacy
of gemcitabine in a pancreatic cancer in vitro model, suggesting
the molecular pathways that are activated and required for
treatments efficacy. Moreover, we decided to in vivo validate the
promising antiproliferative results of the combination in pancrea-
tic tumour xenografts; in our opinion, to gain further knowledge
on the possibility to use Aurora kinase inhibitors in solid tumours,
treatment could send toward a new approach for cancer therapy,
and since in literature the validation of in vitro results of this drug
in multitherapy in colorectal cancer was already available (Nair
et al, 2009a), we focused on the other cancer model.
MATERIALS AND METHODS
Drugs and chemicals
AZD1152-HQPA and AZD1152 were provided by AstraZeneca
Pharmaceuticals (Macclesfield, UK). Stock solutions of AZD1152-
HQPA were prepared at 20mM in DMSO and stored in aliquots at
 201C. Gemcitabine (Gemzar) and oxaliplatin (Eloxatin) were
provided by Eli Lilly and Co. (Indianapolis, IN, USA) and Sanofi-
Synthelabo (Milan, Italy) respectively. Further dilutions were made
in the medium supplemented with 10% foetal bovine serum, 2mM
glutamine, 50000Ul
 1 penicillin and 80mM streptomycin. For
in vivo studies, sterile AZD1152 powder was dissolved in Tris
buffer 0.3 M, pH 9.0, to obtain a solution at the concentration of
25mgml
 1. Gemcitabine (Eli Lilly and Co.) was diluted in sterile
saline solution for in vivo use.
Cell lines
The colon cancer (HCT116 and Colo205) and pancreatic
(MiaPaCa-2) cell lines were kindly provided by Professor M
Coluccia (University of Bari, Bari, Italy) and obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA),
respectively. Cells were cultured in vitro in RPMI supplemented
with 10% foetal bovine serum, 2mM glutamine, 50000Ul
 1
penicillin and 80mM streptomycin in a humidified incubator at
371C with an atmosphere containing 5% CO2.
Cell imaging
Cells incubated with 30 and 300nM AZD1152-HQPA for 1–3 days
were analysed by light inverted microscopy.
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Determination of cell growth inhibition was performed using the
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide
(MTT) assay and by cell counting. The MTT assay for each
concentration responsible for 50% inhibition of cell growth (IC50)
determination and drug combination effectiveness was performed
as described in (Azzariti et al, 2004).
For cell count determination, 1.5 10
5 cells were plated in
35mm Petri dishes, exposed to drug(s), harvested in trypsin and
counted. For IC50 determination, AZD1152-HQPA was given at
concentrations of 3, 30, 300nM, 3 and 30mM for 3 days. The IC50
was defined as the drug concentration yielding a fraction of
affected (no surviving) cells¼0.5, compared with untreated
controls and was calculated utilising the CalcuSyn ver.1.1.4
software (Biosoft, Cambridge, UK). In the combination studies,
AZD1152-HQPA was given at 30 and 300nM and the chemother-
apeutic agents at the concentration reported in each experiment.
To define the best schedule for the combination, either simulta-
neous or sequential utilisation of the two drugs were tested. Each
experiment was carried out in triplicate.
Cell cycle analysis
Cells were harvested, washed twice in ice-cold PBS (pH 7.4), fixed
in 4.5ml of 70% ethanol at  201C and washed once in ice-cold
PBS. The pellet was resuspended in PBS containing 1mgml
 1
RNase, 0.01% NP40 and the cellular DNA was stained with
50mgml
 1 propidium iodide (PI) (Sigma, St Louis, MO, USA).
Cells were stored in ice for at least 1h before analysis. Cell cycle
determinations were performed using a FACScan flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA), and data were
interpreted using the CellQuest software, provided by the
manufacturer.
Cell apoptosis assay
Apoptosis was determined by dual staining with Annexin V-FITC
and PI using the Annexin V-FITC detection kit (BD Transduction)
and by PI following the manufacturer’s protocol and analysed by
flow cytometry with FACScan (Becton Dickinson). Apoptosis was
also determined using BAK-epitope, an early marker of apoptosis.
HCT116 cells were seeded in 96-well plates and 24h later subjected
to different dosing schedules (concurrent or sequential). Cells were
then stained for cell number by Hoechst (nuclei), and apoptosis by
BAK. Images were taken and end points quantified using the
Cellomics Arrayscan II platform (Cummings et al, 2008).
Chromosome number determination
Cells were treated with colcemid 0.5mM for 4h, harvested, washed
twice in PBS and swelled in hypotonic solution (0.075 M potassium
chloride (KCl)) for 10min at room temperature. Cells were fixed
with methanol and acetic acid (3:1), dropped on slides and left
to dry for 24h. Chromosomes were stained with quinacrine 5%
and analysed using a fluorescence microscope (Olympus BX40).
A number of at least 50 metaphases for each specimen were
evaluated.
Western blot analysis
Protein extracts were obtained by homogenisation in RIPA buffer
(0.5 M NaCl, 1% Triton X-100, 0.5% NP40, 1% deoxycolic acid,
3.5mM SDS, 8.3mM Tris–HCl, pH 7.4, 1.6mM Tris base) and
treated with 1mM phenylmethylsulphonyl fluoride. Total proteins
were measured and analysed as described in Azzariti et al (2004).
In particular, 50mg were electrophoretically separated on 10%
acrylamide gel (SDS–PAGE by Laemmli). Signal was detected by
chemoluminescence assay (ECL-Plus, Amersham Life Science,
Little Chalfont, UK). Expression levels were evaluated by densito-
metric analysis using the Quantity One software (Biorad, Hercules,
CA, USA) and b-actin expression levels were used to normalise the
sample values.
Antibodies
The monoclonal antibody anti-Akt (no. 9272), anti-phospho-Akt
(Ser473) (no. 9271), anti-p53(DO-1) (Sc-126) and anti-b-actin
AC-15 (A5441) were provided by Cell Signalling (Milwaukee, WI,
USA), Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
Sigma-Aldrich, respectively. A mouse-HRP and a rabbit-HRP
(Amersham Pharmacia Biotech, Uppsala, Sweden) were used as
secondary antibody. All antibodies were utilised at the recom-
mended dilutions.
Fluorescence immunocytochemistry
Cells were seeded onto coverslips. After overnight incubation, they
were fixed in 3.7% paraformaldehyde, washed and permeabilised
with 0.1% Triton X-100. After saturation with 0.1% gelatin in PBS,
cells were subsequently immunostained overnight with phospho-
specific histone H3 (Ser10) antibody (Upstate, New York, NY,
USA). Cells were then incubated with FITC-conjugated secondary
antibody (Becton Dickinson) for 1h. Nuclei were counterstained
with 0.5lgml
 1 40,6-diamidino-2-phenylindole (DAPI). The images
were captured using a fluorescence microscope (Olympus BX40),
equipped with  20 objective with a SenSys 1401E-Photometrics
charge-coupled device camera. FITC was excited using the 488
laser line and DAPI using the 568 laser line.
In vivo experiments
Animals. CD nu/nu male mice weighing 20g were supplied by
Charles River (Milan, Italy) and were allowed unrestricted access
to food and tap water. Housing and all procedures involving
animals were performed according to the protocol approved by
the Academic Committee for the animal experimentation of the
University of Pisa, in accordance with the European Community
Council Directive 86-609, recognised by the Italian government, on
animal welfare.
MiaPaCa-2 xenografts in nu/nu mice and drug treatments.
MiaPaCa-2 cell viability was assessed by Trypan blue dye
exclusion. On day 0, 1.3 10
6±5% cells per mouse were
inoculated subcutaneously between the scapulae in 0.2ml per
mouse of culture medium without FBS. Animal weights were
monitored and, upon appearance of a subcutaneous mass, tumour
dimensions were measured every 4 days in two perpendicular
directions using callipers. Tumour volume (mm
3) was defined as
follows: ((w1 w2 w2) (p/6)), where w1 and w2 were the
largest and the smallest tumour diameter (mm), respectively.
The mice were randomised into four groups of eight animals.
To treat an established tumour (B100mm
3), from day 15 after
cell inoculation AZD1152, gemcitabine and their respective
vehicles were administered intraperitoneally to mice as follows:
group (1) AZD1152 25mgkg
 1 for 4 consecutive days, followed by
sterile saline (gemcitabine vehicle); group (2) solution of Tris
buffer 0.3 M alone (AZD1152 vehicle) for the first 4 days, followed,
on day 5, by gemcitabine 120mgkg
 1 four times a day at 3-day
intervals (Bocci et al, 2005); group (3) combination treatment of
AZD1152 25mgkg
 1 for 4 consecutive days, followed by
gemcitabine 120mgkg
 1 four times a day at 3-day intervals; and
group (4) AZD1152 vehicle alone, followed by gemcitabine vehicle
alone (control group). After treatment, the mice were observed for
10 days and then killed by an anaesthetic overdose. Moreover, the
%T/C value has been calculated as follows (Bocci et al, 2008):
AZD1152 in pancreatic cancer treatment
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of the control group) 100.
Statistical analysis
All in vitro experiments were performed in triplicate, and results
have been expressed as the mean±standard deviation (s.d.),
unless otherwise indicated. Statistical differences of in vitro and
in vivo data were assessed by ANOVA, followed by the Student–
Newman–Keuls test. P-values lower than 0.05 were considered
significant. Statistical analyses were performed using the GraphPad
Prism software package version 5.0 (GraphPad Software Inc., San
Diego, CA, USA).
RESULTS
AZD1152-HQPA inhibits cell growth in the function of
drug concentration and exposure time
In initial experiments, AZD1152-HQPA, at concentrations ranging
between 3nM and 3mM, given for 1 day, followed by 0–5 days wash
out, failed to show a strong reduction of cell growth by MTT assay
despite the clear effects obtained by cell counts shown in Figure 1.
The experimental conditions have been reported in a previous
analysis (Cummings et al, 2008) and our results suggested that the
MTT assay underestimated the effects of AZD1152-HQPA on cell
number, possibly because the cells increase in size before
undergoing apoptosis. Thus, the following experiments were
designed to evaluate the effectiveness of AZD1152-HQPA alone
and in combination with conventional chemotherapeutic agents,
by direct cell counting.
Of the three cancer cell lines analysed (HCT116, Colo205 and
MiaPaCa-2), the HCT116 cell line was the most sensitive to
AZD1152-HQPA treatment. The effectiveness of AZD1152-HQPA
increased as a function of concentration and time exposure in all
cell lines. In detail, 1-day incubation of HCT116 cells with
AZD1152-HQPA 30nM induced a reduction in cell numbers of
approximately 20, 30 and 80% after 0, 2 and 4 days drug wash out,
respectively (Figure 1B). In the same experimental conditions,
treatment of Colo205 cells reduced cell numbers by approximately
15, 20 and 40%, respectively (data not shown). The effects on cell
growth were greater at higher drug concentrations or after longer
exposure to the drug. For example, treatment with AZD1152-
HQPA 300nM increased cell growth inhibition after 2 days wash
out from 40 to 85% and from 40 to 55% in HCT116 and Colo205
cells, respectively. Conversely, treatment with AZD1152-HQPA for
just 1 day induced only a slight inhibition in MiaPaCa-2 cell
growth, which increased with washout time exposure from 5 to
40% at 0 and 5 days after wash out, respectively.
The choice of chemotherapeutics for the combination experi-
ments was suggested by both their conventional utilisation in
cancer chemotherapy and mechanisms of action, interacting with
our Aurora B kinase inhibitor, that is, oxaliplatin and gemcitabine
in colon and pancreatic cancer in vitro models, respectively. To
define the best schedule for drug combination, AZD1152-HQPA
was administered before, together or after the chemotherapeutic
drugs. Furthermore, pilot kinetic experiments were performed to
find the most effective combination with AZD1152-HQPA after
1 day and 3 days. The conventional chemotherapeutics were
utilised at IC50 concentrations; oxaliplatin was given for 1 day at 50
and 35mM in HCT116 and Colo205 cells, respectively; gemcitabine
was given for 1 day at 28.6mM, followed by 3 days wash out or for
3 days at 1.41mM in MiaPaCa-2 cells. IC50 concentrations were
lower than plasma concentrations in treated patients for gemci-
tabine. Conversely, the oxaliplatin concentration was higher than
plasma concentrations, but compatible with its concentration in
animal model for 1-day oxaliplatin administration (Ostberg et al,
2008; Veltkamp et al, 2008). Initially, we determined the best
schedule of combined administration of AZD1152-HQPA plus
gemcitabine or oxaliplatin in both in vitro models and in Figure 1A
we reported data from MiaPaca-2 cells, which are representative of
those obtained in colon cancer cells. The comparison of the three
different schedules indicates that the best schedule is one in which
the AZD1152 is given before the chemotherapeutic agent and is
independent of AZD1152-HQPA time exposure. Moreover,
AZD1152-HQPA appeared to enhance the effectiveness of gemci-
tabine in a concentration-independent manner between 3 and
300nM in these experimental conditions (Figure 1A). The
evaluation of the ability of AZD1152-HQPA to enhance chemo-
therapeutics cytotoxicity was also measured after giving the two
drugs in the most promising schedule, followed by 1–3 days wash
out, and, as evident in Figure 1B, cell growth inhibition increased
as a function of time. In Figure 1B, all results of AZD1152-HQPA in
combination with oxaliplatin or gemcitabine after 3 days wash
out were statistically different from each chemotherapeutic alone
(P-value o0.05); conversely, at shorter time wash out, only in
HCT116 cells, data were statistically different.
AZD1152-HQPA perturbs cell cycle progression
A strong perturbation of cell cycle progression may be responsible
for the observed reduction in cell growth and this hypothesis has
been investigated in our model. In HCT116 cells, 1-day exposure to
30–300nM AZD1152-HQPA induced an additional round of DNA
synthesis such that cells became 48N and the effect was partially
maintained during a 1–2 days drug washout period, as reported in
Figure 2A. The behaviour was similar in both colon cancer cell
lines (data not shown). In contrast, in MiaPaCa-2 cells, AZD1152-
HQPA at both 30 and 300nM induced cell cycle arrest in mitosis
(4N) soon after 1-day treatment, which was removed following
drug wash out (Figure 2B). To investigate whether the recovery of
cell cycle progression was due to intrinsic resistance of cells,
induction of apoptosis or simply a reduction of AZD1152-HQPA
concentration during the washout period, experiments were
performed by exposing MiaPaCa2 cells to AZD1152-HQPA for 3
days. These experiments showed that the effects of the drug on cell
cycle distribution remained stable over a longer treatment period.
These findings suggest that reversal of the effects of AZD1152-
HQPA after shorter treatment times is due to reduction in drug
concentration rather than a resistance mechanism or induction of
apoptosis because of the absence of a sub-G0 peak (Figure 2C). The
behaviour was similar in all cancer cell lines utilised (data not
shown). In conclusion, AZD1152-HQPA induced a marked
concentration-dependent G2/M-phase cell (4N) accumulation
associated with increased DNA content in all cell lines, which
was dependent on drug concentration. This phenomenon was
reversed with increasing time of drug wash out. Furthermore, cell
cycle analysis was carried out in the combination study in the
colon cancer model in which AZD1152-HQPA was given with
oxaliplatin, which is known to block cells in G2/M phase. Results
showed a higher accumulation of cells with 4N DNA content with a
concomitant increase of cell death (data not shown).
AZD1152-HQPA strongly modifies cellular morphology
and induces endoreduplication
All experiments evidenced major modification in cell structure and
in cell growth features after cell exposure to AZD1152-HQPA. The
effect of treatment with 30 and 300nM AZD1152-HQPA for 1–5
days on cell morphology was determined by light microscopy and
showed major modifications in cell structure and in cell growth
features, in all cell lines. In particular, treated cells were larger than
untreated cells and this was confirmed as an increase in forward
light scatter during flow cytometric cell cycle analysis; in Figure 3A
results from MiaPaCa-2 cells are shown. The effects of AZD1152-
HQPA on chromosomal localisation and structure were examined
AZD1152 in pancreatic cancer treatment
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abnormalities in chromosomal localisation at the centromere and
mitotic spindles, together with endoreduplication associated with
inhibition of cytokinesis. Data from the MiaPaCa-2 pancreatic cell
line are reported in Figure 3 and showed a strong induction of
endoreduplication, as a function of drug concentration and time
exposure, and abnormal prometaphases (Figure 3B). To further
confirm the ability of AZD1152-HQPA to enhance polyploidia and
to inhibit chromosome alignment and segregation, chromosome
number and localisation were evaluated. Cells were treated with 30
and 300nM AZD1152-HQPA for 1 day with or without a
subsequent 1–3 days wash out. Treated cells displayed a strong
increase of chromosome number of approximately two- to
four-fold greater than in control (untreated) cells after only
1-days treatment (Figure 3C), which was particularly evident at
higher concentrations (300nM AZD1152-HQPA) in both colon and
pancreatic cancer cell lines, also shown by a substantial increase of
44N subpopulations on flow cytometry analysis.
Concurrent treatment of AZD1152-HQPA with oxaliplatin
enhances apoptosis in colon cell line
It has previously been shown that inhibition of Aurora B activity
by treatment with AZD1152 induces failure of cell division, leading
ultimately to apoptosis (Wilkinson et al, 2007). Here, we
investigated the effect of AZD1152 in combination with oxaliplatin
on cell survival and cell growth. In vitro treatment of AZD1152-
HQPA, followed by drug wash out induced a significant cell growth
arrest, but a minimal effect of apoptosis as measured by Annexin V
or BAK staining (o10% of positive cells) (Figure 4). When cells
were concurrently treated with AZD1152-HQPA and oxaliplatin,
an enhanced inhibitory effect on cell growth and cell survival was
observed compared with monotherapy (Figure 4). Two-way
ANOVA statistical analysis of the data shows a significant
difference in the mean values among the different concentrations
of oxaliplatin (Po0.001) when simultaneously administrated with
AZD1152-HQPA in HCT116 cells (Figure 4B). In comparison to
monotherapy, where the two drugs are combined sequentially
with 24h drug wash out, an equal or small beneficial effect was
observed (Figures 4B and C). These data suggest that the optimal
schedule for combining AZD1152 and oxaliplatin within the time
frame chosen for the experiments is concurrent treatment.
An increase of 20% in apoptosis was observed when oxaliplatin
was administered after AZD1152-HQPA, by Annexin V assay
(data not shown). Importantly, none of the combination dosing
schedules of AZD1152-HQPA with oxaliplatin resulted in an
antagonistic effect compared with either monotherapy (data
not shown).
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sAZD1152-HQPA inhibits survival pathways as well as
Aurora B kinase activity
The ability of AZD1152-HQPA to inhibit histone H3 phosphoryla-
tion, as a function of drug concentration, has been evaluated by
immunofluorescence and western blotting analysis. Levels of
phosphorylated histone H3 remained low during the drug washout
time, showing that the Aurora B kinase activity was stably
inhibited; in Figure 5A, results from MiaPaca-2 cells are reported
and they are representative of all in vitro models. In addition to its
specific cell target, survival and proliferation pathway modulation
was also investigated, by determining Akt and Erk1/2 by western
blotting. Results evidenced the absence of drug ability to modulate
the total forms of both proteins (not shown). Conversely,
decreased Akt phosphorylation was associated with drug treat-
ment, probably because the cells are undergoing apoptosis; in
MiaPaCa-2 cells, as reported in Figure 5B, p-Akt recovered the
basic condition after 3 days drug wash out, a similar modulation
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swas observed in colon cancer models, but the recovery, after 3 days
wash out, reached at maximum 80% (data not shown). Further-
more, an increase in p53 was associated with AZD1152-HOPA
treatment in colon cancer cell lines compared with the pancreatic
cell line, in which its modulation is limited. These findings suggest
that the increase in cell susceptibility is the start of the cell death
process (Figure 5D).
AZD1152, gemcitabine and their consecutive combination
in vivo
Our in vitro results suggest that AZD1152 could be an enhancer of
the efficacy of gemcitabine in pancreatic tumour treatment and so
we conducted in vivo studies to validate these findings. MiaPaCa-2
cells injected s.c. in CD nu/nu mice grew quite rapidly and tumour
masses became detectable 7 days after xenotransplantation.
Tumours in control animals showed a progressive enlargement
in their dimensions and a marked growth after B30 days; a mean
volume of B2500mm
3 was reached at day 42 when the animals of
the control group were killed (Figure 6A). As expected, both
gemcitabine and AZD1152 at the MTDs were able to significantly
inhibit tumour growth in a similar extent as compared with
controls, as well as their combination (Figure 6A). In the group of
animals receiving the consecutive combination of AZD1152 and
gemcitabine, the average reduction in tumour growth was more
than double than the single drugs already by day 26 (e.g., the
1-days AZD1152-HQPA
plus 5 days drug wash out
1-day AZD1152-HQPA 30nM Ctrl
30nM AZD1152-HQPA 1D 300nM AZD1152-HQPA 1D
1 mm 1 mm 1 mm
1 mm 1 mm
Ctrl 3nM 30nM
300nM 3M
Ctrl
Figure 3 Morphological changes by AZD1152-HQPA exposure. (A) Increase in MiaPaCa-2 cell size induced by AZD1152-HQPA exposure at various
concentrations and wash out. (B) Chromosome alignment and segregation prevented by AZD1152-HQPA in MiaPaCa-2 cells induced abnormal
prometaphase detected by immunofluorescence (tubulin staining in green and DAPI in blue). (C) MiaPaCa-2 cells were incubated with AZD1152-HQPA
for 1 day and the chromosome number was determined by quinacrine assay utilising fluorescence microscopy, as described in Materials and Methods
section. A number of at least 50 metaphases for each specimen were evaluated.
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scalculated T/C value was 22% of the combination vs 47% of
AZD1152 alone and 51% of gemcitabine alone) and the tumour
growth curve showed a marked delay after the interruption of the
treatments if compared with the ones of single compounds, as
shown in Figure 6A (at day 42, T/C value 34% of
AZD1152þgemcitabine vs 56% of AZD alone and 75% of
gemcitabine alone).
Figure 6B shows the toxicity profiles of the four different
schedules. All the schedules were favourable and acceptable, with
no loss of weight throughout the course of the treatment
(Figure 6B). It is worth noting that the animals treated with the
combination reached body weights similar to those treated with
vehicles alone, confirming the safety of the association despite its
higher therapeutic effect.
DISCUSSION
There is considerable interest in combining novel targeted agents
with standard chemotherapeutics to enhance efficacy. It is
becoming increasingly obvious that the schedule of administration
influences the success of these combination strategies (Azzariti
et al, 2004, 2008; Bocci et al, 2005).
In the case of the emerging class of Aurora kinase inhibitors,
studies on several promising drug combinations are currently in
progress, such as taxane plus Aurora A RNA interference,
MK-0457 plus etoposide or doxorubicin, docetaxel plus Aurora
A short hairpin RNA and AZD1152 plus radiotherapy in various
solid cancer models (Hata et al, 2005; Lee et al, 2006; Sun et al,
2007; Tanaka et al, 2007; Yang et al, 2007; Tao et al, 2008).
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Figure 4 Effect of AZD1152-HQPA in combination with oxaliplatin on cell growth and apoptosis. HCT116 cells were seeded in 96-well plates.
After 24h, cells were subjected to concurrent dosing schedule (A and B) or a sequential dosing schedule (C). Cells were then stained for cell number by
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representative of three independent experiments. Columns, mean; bars, s.e. *Po0.05 vs oxaliplatin 0mM (two-way ANOVA); WO¼washout.
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sActually, several clinical trials are ongoing with this class of drug
and briefly MK-0457, MLN8237, PHA-739358, PF-03814735 are in
phase II (www.clinicaltrials.gov).
However, little is known about the mechanism of action of
Aurora kinase inhibitors in combination with radio- and
chemotherapy at the molecular level.
Our in vitro characterisation showed that AZD1152-HQPA
monotherapy, the active form of the phosphate prodrug AZD1152,
inhibited cell growth and induced apoptosis in colon and
pancreatic cancer cell lines in a concentration- and time-
dependent manner. The induction of apoptosis detected with the
Annexin V and immunoflurescence assays was not reflected as an
increase in a sub-G0/G1 peak population by flow cytometry. We
believe that this is explained by the fact that DNA fragmentation
associated with apoptosis occurs in a cell population that has
undergone endoreduplication to become 44N. It has been
suggested by Aihara et al (2009) that this makes detection of a
sub-G0/G1 peak by conventional flow cytometry difficult. Data
concerning the effects of AZD1152-HQPA on apoptosis are scant,
although our analysis seems to be in disagreement with the results
of Oke et al (2009), who reported that the Aurora B kinase
inhibitor induced a strong increase in an Annexin V-positive cell
fraction in studies in primary AML cells and cell lines. However,
our experimental conditions are markedly different from those of
Oke et al (2009) in that they involve prolonged drug exposure
times, and it is likely that after a 1-day exposure, followed by 1-day
drug washout period, the number of apoptotic cells that can be
detected will be rather less than that seen after 4 days of
continuous drug exposure. In addition, Oke et al (2009) suggest
that most cells progress from polyploidy to apoptosis after
prolonged drug exposure. In this, it appears that cells can
maintain the ability to overcome polyploidy and can begin to
divide after shorter exposure times. This finding suggests that
1-day exposure to AZD1152-hQPA might be sufficient to sensitise
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Figure 5 AZD1152-HQPA-dependent modulation of cell pathways. (A) MiaPaCa-2 cells were incubated with AZD1152-HQPA for 1 day, followed by
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and western blotting. (B and C) Cells were incubated with AZD1152-HQPA and protein extracts were analysed by western blotting. The amount of p-AKT
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stumour cells to the effects of conventional cytotoxic agents,
thereby reducing toxic effects. This ability to overcome cell cycle
impairment and to recover the ability to enter mitosis seems
evident in solid tumour cell lines, but not in an AML model, in
which 48h exposure to AZD1152-hQPA reduced the ability of cells
to undergo clonal growth, when replated in fresh medium,
suggesting a inverse correlation between recovery of cell growth
ability and DNA increase (Walsby et al, 2008).
Our results are in agreement with those produced by Nair et al
(2009a), who reported a small induction in apoptosis after 48h
treatment of HCT116 cells with AZD1152-HQPA. Our study is also
in agreement with a recent study in which CPT-11 enhanced
AZD1152 activity in a schedule-dependent manner (Nair et al,
2009a). In this study, the best schedule of administration was when
the Aurora kinase inhibitor was given before the cytotoxic drug.
We also showed similar schedule-dependent effects when combin-
ing AZD1152-HQPA with either oxaliplatin or gemcitabine.
A possible explanation lies in the capability of AZD1152-HQPA
to induce polyploidy, which should be responsible for the
enhanced chemotherapeutics ability to induce apoptosis on the
endoreduplicating cells. AZD1152-HQPA exerts its activity
through the inhibition of histone 3 phosphorylation even if it also
modulates other signal-transduction pathways, such as survival
pathways that involve the tumour suppressor protein p53. In the
analysis of cell targets modulated by AZD1152, we focused our
attention on p53 modulation, and in agreement with Nair et al
(2009b), we found that AZD1152 was associated with an increase in
the expression level of this tumour suppressor protein, but only
when it was wild type. Conversely in the pancreatic cancer cell line,
with mutated p53, modulation was absent even if its pharmaco-
logical treatment, in vitro and in vivo, was promising.
Our study stresses the importance in defining the best drug
sequencing for combined administration to optimise a novel
therapeutic approach (Xu et al, 2003; Azzariti et al, 2006a,b). The
possibility to utilise AZD1152-HQPA as enhancer of the effective-
ness of oxaliplatin and gemcitabine was verified in colon and
pancreatic cancer models, respectively. Promising results, obtained
in both models, especially using the schedule in which AZD1152-
HQPA was given before gemcitabine or oxaliplatin, support a
positive role for AZD1152 as an enhancer of the antitumour effects
of standard of care chemotherapy in patients with colorectal and
pancreatic cancer. We decided to validate our hypothesis in an
animal model starting with the pancreatic cancer model utilising a
pancreatic tumour xenograft. Indeed, the consecutive combination
of AZD1152 with gemcitabine seems to suggest the possible
importance of a sequence-dependent effect because the sequential
association was on average more effective than either single-agent
therapy in inhibiting and delaying the tumour growth, without
inducing important toxicities. Both these promising aspects and
the knowledge of specific drug sequencing could be very helpful
for the future planning of preclinical and, above all, clinical studies
to avoid any failures in the AZD1152 clinical development.
In a recent report, Aihara et al (2009) suggested the utilisation of
an orthotopic xenograft model instead of or together with a
subcutaneous xenograft model because the benefits are easy
evaluation of tumour growth and a correlation of the biological
response of drugs to the natural tumour microenvironment,
respectively. We agree with this idea, and in the future, we will
evaluate AZD1152 in combination with gemcitabine in orthotopic
xenograft models of pancreatic cancer. However, even if some
promising data are available on the preclinical and clinical
utilisation of this class of target-oriented drugs, some points to
consider include: (1) to further investigate genetic instability in
these cancers, which through deregulation of Aurora kinases
contributes to the acquisition of genetic aberrations, promoting
the development of malignancy; (2) to exactly define the optimal
drug schedules to maximise target inhibition; and (3) to identify
predictive biomarkers, to select patients for treatment with an
Aurora kinase inhibitor, different from phosphorylated histone
H3, which is a regulator of mitosis, and thus, it is not a cancer-
specific inhibitor in the strictest sense.
As reported, AZD1152 has been already utilised in a phase I
clinical trials in patients with advanced solid tumours, in which
this drug showed to induce a significant disease stabilisation, and
in phase I/II trials in patients with advanced acute myeloid
leukaemia showing an acceptable tolerability profile and an overall
clinical response rate of 23% (Lowenberg et al, 2009; Boss et al,
2010). Our opinion is that the in vitro and in vivo data strongly
suggest the use of AZD1152 in the treatment of pancreatic cancer,
and these data are consistent with clinical trials already ongoing in
pancreatic cancer using drugs inhibiting Aurora kinases, such as
MLN8054 and AS703569, selective inhibitors of Aurora A kinase
and Aurora B kinase, respectively (www.clinicaltrials.gov).
In agreement with other literature data, our in vitro and in vivo
results point toward additive and synergistic anticancer effects
between AZD1152 and conventional chemotherapy, and our hope
lies in the possibility to translate such combinations into the clinic.
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Figure 6 In vivo effects of AZD1152, gemcitabine and the sequential
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